Indoor Woodsmoke PM and Asthma



Status:Completed
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:10 - 17
Updated:11/8/2014
Start Date:December 2008
End Date:January 2013
Contact:Curtis W Noonan, Ph.D.
Email:curtis.noonan@umontana.edu
Phone:406-243-4957

Use our guide to learn which trials are right for you!

Indoor Woodsmoke PM and Asthma: a Randomized Trial

Although particulate matter (PM) exposures have been linked with poor respiratory health
outcomes, most of these studies have focused on airsheds with urban and industrial sources
of PM2.5. Woodsmoke-derived PM also contributes to ambient PM in these urban areas, and is
the major source of PM in many US rural or peri-urban areas, as well as in many communities
within developing countries. This study will focus on indoor air quality and clinically
relevant changes in health effects among asthmatics living in homes whose primary heating
sources are non EPA-certified woodstoves. The Primary Aim of this study is to assess the
efficacy of residential interventions to reduce indoor PM exposure from woodstoves and the
corresponding improvements in quality of life and health outcomes for asthmatic children.
The study area for this project will be three rural communities in western Montana and
Idaho, including one Indian Reservation. This study will use a three arm (Tx1, Tx2, and
Tx3) randomized placebo-controlled intervention trial. The interventions will be at the
household level, and exposure and outcomes will be assessed for one asthmatic child in each
household. Households in Tx1 will receive inactive high efficiency particulate air (HEPA)
devices and will serve as the placebo group. Households in Tx2 will receive a new
EPA-certified woodstove, while households in Tx3 will receive active HEPA devices. The
Secondary Aims of this study are to assess the impact of these interventions on residential
PM2.5 exposures and other health outcomes. Secondary exposure outcomes measured prior to
and following the intervention will include PM2.5 mass, chemical woodsmoke markers on PM2.5
filters (including levoglucosan and abietic acids), and biomarkers of woodsmoke exposure.
Secondary asthma-related health outcomes measured prior to and following the intervention
will include peak expiratory flow (PEF) and forced expiratory volume in first second (FEV1),
biomarkers in exhaled breath condensate, and frequency of asthma symptoms, medication usage,
and healthcare utilization. To our knowledge, this will be the first randomized trial in
the US to utilize a woodsmoke intervention to assess the impact of the consequent reductions
in indoor PM on health outcomes in a susceptible population. The results from this project
will be translatable to other regions in the US and the world where biomass burning is
commonly used for heating and cooking.


Inclusion Criteria:

- children with moderate to severe asthma living in homes with non EPA-certified
woodstove used for heating.

Exclusion Criteria:

-
We found this trial at
1
site
Missoula, Montana 59812
?
mi
from
Missoula, MT
Click here to add this to my saved trials